NCT00015964 2013-09-05
ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck
University of Chicago
Phase 2 Completed
Clinical Trials
10 trialsNCT00024089 2013-02-11
Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00033449 2013-01-25
Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00068497 2013-01-14
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase NA Completed
NCT00352105 2012-11-05
Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT00083057 2012-03-15
Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00206219 2011-01-27
Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)
AstraZeneca
Phase 3 Completed
NCT00233636 2011-01-27
Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck
AstraZeneca
Phase 2 Withdrawn
NCT00229723 2009-08-04
IRESSAâ„¢ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma
AstraZeneca
Phase 2 Completed
NCT00195078 2007-07-20
Safety Trial of IRESSA, Cisplatin and Radiation Therapy for Patients With Head and Neck Cancer
Weill Medical College of Cornell University
Phase 1/2 Terminated